38 patents
Utility
Methods of Treating Diseases and Disorders
28 Dec 23
The present disclosure relates to methods of treating certain diseases and disorders (e.g., IRAK4-associated diseases and disorders).
Reinhard von Roemeling, Andrey Ugolkov, Robert Martell
Filed: 17 Nov 21
Utility
Compositions and Methods for Treating Diseases and Disorders
5 Oct 23
The present disclosure relates to methods of treating certain diseases and disorders (e.g., IRAK4 associated diseases and disorders).
Reinhard von Roemeling, Elizabeth Martinez, Robert Martell
Filed: 30 Apr 21
Utility
Phosphoinositide 3-KINASE Inhibitors with a Zinc Binding Moiety
20 Jul 23
The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer.
Xiong Cai, Haixiao Zhai, Chengjung Lai, Changgeng Qian
Filed: 13 Jan 23
Utility
Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
23 May 23
Xiong Cai, Haixiao Zhai, Chengjung Lai, Changgeng Qian, Rudi Bao
Filed: 9 Sep 21
Utility
Crystal forms of immunomodulators
9 May 23
The invention relates to crystalline forms of a 3-substituted 1,2,4-oxadiazole compound, including an anhydrous crystalline form, methods of their preparation, and related pharmaceutical preparations thereof.
Shu Yu
Filed: 17 Jun 21
Utility
Conjoint Therapies for Immunomodulation
16 Mar 23
The present disclosure relates to methods comprising administering compounds that inhibit VISTA and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways with a compound that inhibits TIM-3 and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways.
Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Raghuveer K. Ramachandra, Adam S. Lazorchak, Timothy L. Wyant
Filed: 5 Oct 22
Utility
Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
7 Mar 23
The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer.
Xiong Cai, Haixiao Zhai, Chengjung Lai, Changgeng Qian
Filed: 27 Jan 22
Utility
Fused amino pyridine as HSP90 inhibitors
24 Jan 23
The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.
Xiong Cai, Changgeng Qian, Haixiao Zhai
Filed: 29 Oct 20
Utility
Phosphoinositide 3-KINASE Inhibitors with a Zinc Binding Moiety
22 Dec 22
The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer.
Xiong Cai, Haixiao Zhai, Chengjung Lai, Changgeng Qian
Filed: 27 Jan 22
Utility
Compounds and Compositions for Treating Hematological Disorders
24 Nov 22
The present invention provides methods of treating hematological disorders and solid malignant tumors, using substituted indazole compounds and pharmaceutically acceptable salts thereof.
Robert Booher
Filed: 30 Dec 21
Utility
Conjoint therapies for immunomodulation
15 Nov 22
The present disclosure relates to methods comprising administering compounds that inhibit VISTA and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways with a compound that inhibits TIM-3 and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways.
Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Raghuveer K. Ramachandra, Adam S. Lazorchak, Timothy L. Wyant
Filed: 31 Oct 18
Utility
Combination Therapies for the Treatment of Cancer
20 Oct 22
The present disclosure relates to methods of treating certain diseases and disorders (e.g., cancer) with a combination of an IRAK4 inhibitor, a BCL-2 inhibitor, and a nucleoside analog.
Reinhard von Roemeling, Andrey Ugolkov
Filed: 25 Feb 22
Utility
Combination Therapy with a Phosphoinositide 3-KINASE Inhibitor with a Zinc Binding Moiety
11 Aug 22
Jing Wang, Troy David Patterson, Ze Tian
Filed: 21 Dec 21
Utility
Phosphoinositide 3-KINASE Inhibitor with a Zinc Binding Moiety
2 Jun 22
Xiong Cai, Haixiao Zhai, Chengjung Lai, Changgeng Qian, Rudi Bao
Filed: 9 Sep 21
Utility
Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
1 Mar 22
The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer.
Xiong Cai, Haixiao Zhai, Chengjung Lai, Changgeng Qian
Filed: 23 Dec 20
Utility
Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
1 Feb 22
Jing Wang, Troy David Patterson, Ze Tian
Filed: 10 Sep 19
Utility
Crystal Forms of Immunomodulators
9 Dec 21
The invention relates to crystalline forms of a 3-substituted 1,2,4-oxadiazole compound, including an anhydrous crystalline form, methods of their preparation, and related pharmaceutical preparations thereof.
Shu Yu
Filed: 17 Jun 21
Utility
Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
5 Oct 21
Xiong Cai, Haixiao Zhai, Chengjung Lai, Changgeng Qian, Rudi Bao
Filed: 7 Jan 20
Utility
Fused Amino Pyridine As HSP90 Inhibitors
23 Sep 21
The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.
Xiong Cai, Changgeng Qian, Haixiao Zhai
Filed: 29 Oct 20
Utility
Phosphoinositide 3-KINASE Inhibitors with a Zinc Binding Moiety
15 Jul 21
The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer.
Xiong Cai, Haixiao Zhai, Chengjung Lai, Changgeng Qian
Filed: 23 Dec 20